<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Frutiger-UltraBlack,Bold" color="#4d67ad"/>
	<fontspec id="font1" size="9" family="Frutiger-UltraBlack,Bold" color="#007682"/>
	<fontspec id="font2" size="9" family="Courier" color="#007682"/>
	<fontspec id="font3" size="9" family="Frutiger-Light" color="#000000"/>
	<fontspec id="font4" size="9" family="Arial" color="#000000"/>
	<fontspec id="font5" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font6" size="24" family="Frutiger-UltraBlack,Bold" color="#000000"/>
	<fontspec id="font7" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font8" size="14" family="GillSans-Light" color="#000000"/>
	<fontspec id="font9" size="16" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font10" size="15" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font11" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font12" size="8" family="Giovanni-Book" color="#ffffff"/>
	<fontspec id="font13" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font14" size="10" family="GillSans" color="#000000"/>
	<fontspec id="font15" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font16" size="8" family="GillSans" color="#000000"/>
	<fontspec id="font17" size="8" family="GillSans,Italic" color="#000000"/>
	<fontspec id="font18" size="8" family="GillSans,Bold" color="#000000"/>
<text top="44" left="508" width="16" height="9" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/"><b>Bio</b></a></text>
<text top="44" left="525" width="22" height="9" font="font1" id="p1_t2" reading_order_no="2" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/"><b>Med</b></a></text>
<text top="44" left="548" width="27" height="9" font="font3" id="p1_t3" reading_order_no="3" segment_no="1" tag_type="title"><a href="http://www.biomedcentral.com/">Central</a></text>
<text top="756" left="508" width="46" height="10" font="font4" id="p1_t4" reading_order_no="63" segment_no="23" tag_type="text">Page 1 of 5</text>
<text top="769" left="432" width="122" height="8" font="font5" id="p1_t5" reading_order_no="64" segment_no="24" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="35" left="55" width="434" height="23" font="font6" id="p1_t6" reading_order_no="0" segment_no="0" tag_type="title"><b>Journal of Autoimmune Diseases</b></text>
<text top="86" left="502" width="79" height="10" font="font7" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="title"><a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="87" left="55" width="50" height="13" font="font8" id="p1_t8" reading_order_no="5" segment_no="3" tag_type="title">Research</text>
<text top="105" left="55" width="499" height="15" font="font9" id="p1_t9" reading_order_no="6" segment_no="4" tag_type="title"><b>Evaluation of autoantibodies to common and neuronal cell antigens </b></text>
<text top="123" left="55" width="220" height="15" font="font9" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="title"><b>in Chronic Fatigue Syndrome</b></text>
<text top="140" left="55" width="276" height="14" font="font10" id="p1_t11" reading_order_no="8" segment_no="5" tag_type="text">Suzanne D Vernon* and William C Reeves</text>
<text top="176" left="55" width="499" height="8" font="font11" id="p1_t12" reading_order_no="9" segment_no="6" tag_type="text">Address: Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, </text>
<text top="185" left="55" width="71" height="8" font="font11" id="p1_t13" reading_order_no="10" segment_no="6" tag_type="text">Georgia 30333, USA</text>
<text top="200" left="55" width="283" height="8" font="font11" id="p1_t14" reading_order_no="11" segment_no="7" tag_type="text">Email: Suzanne D Vernon* - svernon@cdc.gov; William C Reeves - wcr1@cdc.gov</text>
<text top="211" left="55" width="92" height="8" font="font11" id="p1_t15" reading_order_no="12" segment_no="8" tag_type="text">* Corresponding author  <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15916704">  </a></text>
<text top="359" left="55" width="196" height="8" font="font12" id="p1_t16" reading_order_no="25" segment_no="16" tag_type="not_found">chronic fatigue syndromeCFSantibodiesautoantibodies</text>
<text top="388" left="112" width="44" height="10" font="font13" id="p1_t17" reading_order_no="26" segment_no="17" tag_type="title"><b>Abstract</b></text>
<text top="403" left="112" width="385" height="9" font="font14" id="p1_t18" reading_order_no="27" segment_no="18" tag_type="text">People with chronic fatigue syndrome (CFS) suffer from multiple symptoms including fatigue,</text>
<text top="414" left="112" width="386" height="9" font="font14" id="p1_t19" reading_order_no="28" segment_no="18" tag_type="text">impaired memory and concentration, unrefreshing sleep and musculoskeletal pain. The exact</text>
<text top="426" left="112" width="386" height="9" font="font14" id="p1_t20" reading_order_no="29" segment_no="18" tag_type="text">causes of CFS are not known, but the symptom complex resembles that of several diseases that</text>
<text top="438" left="112" width="386" height="9" font="font14" id="p1_t21" reading_order_no="30" segment_no="18" tag_type="text">affect the immune system and autoantibodies may provide clues to the various etiologies of CFS.</text>
<text top="450" left="112" width="386" height="9" font="font14" id="p1_t22" reading_order_no="31" segment_no="18" tag_type="text">We used ELISA, immunoblot and commercially available assays to test serum from subjects</text>
<text top="461" left="112" width="386" height="9" font="font14" id="p1_t23" reading_order_no="32" segment_no="18" tag_type="text">enrolled in a physician-based surveillance study conducted in Atlanta, Georgia and a population-</text>
<text top="473" left="112" width="386" height="9" font="font14" id="p1_t24" reading_order_no="33" segment_no="18" tag_type="text">based study in Wichita, Kansas for a number of common autoantibodies and antibodies to neuron</text>
<text top="485" left="112" width="385" height="9" font="font14" id="p1_t25" reading_order_no="34" segment_no="18" tag_type="text">specific antigens. Subsets of those with CFS had higher rates of antibodies to microtubule-</text>
<text top="497" left="112" width="386" height="9" font="font14" id="p1_t26" reading_order_no="35" segment_no="18" tag_type="text">associated protein 2 (MAP2) (p = 0.03) and ssDNA (p = 0.04). There was no evidence of higher</text>
<text top="508" left="112" width="386" height="9" font="font14" id="p1_t27" reading_order_no="36" segment_no="18" tag_type="text">rates for several common nuclear and cellular antigens in people with CFS. Autoantibodies to</text>
<text top="520" left="112" width="386" height="9" font="font14" id="p1_t28" reading_order_no="37" segment_no="18" tag_type="text">specific host cell antigens may be a useful approach for identifying subsets of people with CFS,</text>
<text top="532" left="112" width="223" height="9" font="font14" id="p1_t29" reading_order_no="38" segment_no="18" tag_type="text">identify biomarkers, and provide clues to CFS etiologies.</text>
<text top="581" left="55" width="60" height="10" font="font13" id="p1_t30" reading_order_no="39" segment_no="19" tag_type="title"><b>Background</b></text>
<text top="593" left="55" width="241" height="9" font="font15" id="p1_t31" reading_order_no="40" segment_no="21" tag_type="text">Chronic fatigue syndrome (CFS) is defined as persistent or</text>
<text top="604" left="55" width="241" height="9" font="font15" id="p1_t32" reading_order_no="41" segment_no="21" tag_type="text">relapsing fatigue that has occurred for at least 6 months, is</text>
<text top="616" left="55" width="241" height="9" font="font15" id="p1_t33" reading_order_no="42" segment_no="21" tag_type="text">not alleviated by rest, and causes substantial reduction in</text>
<text top="628" left="55" width="241" height="9" font="font15" id="p1_t34" reading_order_no="43" segment_no="21" tag_type="text">activities. The fatigue cannot be explained by medical or</text>
<text top="640" left="55" width="241" height="9" font="font15" id="p1_t35" reading_order_no="44" segment_no="21" tag_type="text">psychiatric conditions and must be accompanied by at</text>
<text top="651" left="55" width="241" height="9" font="font15" id="p1_t36" reading_order_no="45" segment_no="21" tag_type="text">least 4 of 8 specified symptoms (unusual post exertional</text>
<text top="663" left="55" width="241" height="9" font="font15" id="p1_t37" reading_order_no="46" segment_no="21" tag_type="text">fatigue, impaired memory or concentration, unrefreshing</text>
<text top="675" left="55" width="241" height="9" font="font15" id="p1_t38" reading_order_no="47" segment_no="21" tag_type="text">sleep, headaches, muscle pain, joint pain, sore throat, and</text>
<text top="687" left="55" width="241" height="9" font="font15" id="p1_t39" reading_order_no="48" segment_no="21" tag_type="text">tender cervical node<a href="">s) [1]. Th</a>ere is considerable discrep-</text>
<text top="698" left="55" width="241" height="9" font="font15" id="p1_t40" reading_order_no="49" segment_no="21" tag_type="text">ancy in results between studies from different institutions;</text>
<text top="710" left="55" width="241" height="9" font="font15" id="p1_t41" reading_order_no="50" segment_no="21" tag_type="text">so as yet, there are no characteristic signs or laboratory</text>
<text top="581" left="313" width="241" height="9" font="font15" id="p1_t42" reading_order_no="51" segment_no="20" tag_type="text">markers of CFS and its pathophysiology has not been elu-</text>
<text top="593" left="313" width="48" height="9" font="font15" id="p1_t43" reading_order_no="52" segment_no="20" tag_type="text">cidated<a href=""> [2].</a></text>
<text top="616" left="313" width="241" height="9" font="font15" id="p1_t44" reading_order_no="53" segment_no="22" tag_type="text">This lack of diagnostic signs or laboratory markers not-</text>
<text top="628" left="313" width="241" height="9" font="font15" id="p1_t45" reading_order_no="54" segment_no="22" tag_type="text">withstanding, many manifestations of CFS resemble those</text>
<text top="640" left="313" width="241" height="9" font="font15" id="p1_t46" reading_order_no="55" segment_no="22" tag_type="text">of musculoskeletal and infectious diseases [<a href="">3</a>]. In large</text>
<text top="651" left="313" width="241" height="9" font="font15" id="p1_t47" reading_order_no="56" segment_no="22" tag_type="text">part, the illnesses caused by these diseases reflect immune</text>
<text top="663" left="313" width="241" height="9" font="font15" id="p1_t48" reading_order_no="57" segment_no="22" tag_type="text">system activation and there is evidence for immune sys-</text>
<text top="675" left="313" width="241" height="9" font="font15" id="p1_t49" reading_order_no="58" segment_no="22" tag_type="text">tem dysfunction in some cases of CFS. In particular, anti-</text>
<text top="687" left="313" width="241" height="9" font="font15" id="p1_t50" reading_order_no="59" segment_no="22" tag_type="text">nuclear antibodies (ANA) and other common</text>
<text top="698" left="313" width="241" height="9" font="font15" id="p1_t51" reading_order_no="60" segment_no="22" tag_type="text">autoantibodies have been evaluated in people with CFS:</text>
<text top="710" left="313" width="241" height="9" font="font15" id="p1_t52" reading_order_no="61" segment_no="22" tag_type="text">unfortunately, with variable results. For example, one</text>
<text top="722" left="313" width="241" height="9" font="font15" id="p1_t53" reading_order_no="62" segment_no="22" tag_type="text">study found that 52% of tertiary care- CFS referral-patients</text>
<text top="254" left="55" width="76" height="7" font="font16" id="p1_t54" reading_order_no="13" segment_no="9" tag_type="text">Published: 25 May 2005</text>
<text top="268" left="55" width="97" height="7" font="font17" id="p1_t55" reading_order_no="14" segment_no="12" tag_type="text"><i>Journal of Autoimmune Diseases</i></text>
<text top="268" left="152" width="22" height="7" font="font16" id="p1_t56" reading_order_no="15" segment_no="12" tag_type="text"> 2005, </text>
<text top="268" left="175" width="4" height="7" font="font18" id="p1_t57" reading_order_no="16" segment_no="12" tag_type="text"><b>2</b></text>
<text top="268" left="179" width="6" height="7" font="font16" id="p1_t58" reading_order_no="17" segment_no="12" tag_type="text">:5</text>
<text top="268" left="194" width="88" height="7" font="font16" id="p1_t59" reading_order_no="18" segment_no="12" tag_type="text">doi:10.1186/1740-2557-2-5</text>
<text top="254" left="310" width="78" height="7" font="font16" id="p1_t60" reading_order_no="23" segment_no="10" tag_type="text">Received: 19 April 2005</text>
<text top="263" left="310" width="76" height="7" font="font16" id="p1_t61" reading_order_no="24" segment_no="11" tag_type="text">Accepted: 25 May 2005</text>
<text top="282" left="55" width="228" height="7" font="font16" id="p1_t62" reading_order_no="19" segment_no="13" tag_type="text"><a href="http://www.jautoimdis.com/content/2/1/5">This article is available from: http://www.jautoimdis.com/content/2/1/5</a></text>
<text top="297" left="55" width="190" height="7" font="font16" id="p1_t63" reading_order_no="20" segment_no="14" tag_type="text">Â© 2005 Vernon and Reeves; licensee BioMed Central Ltd. </text>
<text top="306" left="55" width="492" height="7" font="font16" id="p1_t64" reading_order_no="21" segment_no="15" tag_type="text">This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens<a href="http://creativecommons.org/licenses/by/2.0">e (http://creativecommons.org/licenses/by/2.0), </a></text>
<text top="315" left="55" width="400" height="7" font="font16" id="p1_t65" reading_order_no="22" segment_no="15" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
</page>
</pdf2xml>
